556 related articles for article (PubMed ID: 1531956)
1. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G
Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Bizik J; Lizonová A; Stephens RW; Grófová M; Vaheri A
Cell Regul; 1990 Nov; 1(12):895-905. PubMed ID: 1712633
[TBL] [Abstract][Full Text] [Related]
4. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
Tsuboi R; Rifkin DB
Int J Cancer; 1990 Jul; 46(1):56-60. PubMed ID: 2142142
[TBL] [Abstract][Full Text] [Related]
5. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
8. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
Brunner G; Reimbold K; Meissauer A; Schirrmacher V; Erkell LJ
Exp Cell Res; 1998 Mar; 239(2):301-10. PubMed ID: 9521847
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.
López-Alemany R; Longstaff C; Hawley S; Mirshahi M; Fábregas P; Jardí M; Merton E; Miles LA; Félez J
Am J Hematol; 2003 Apr; 72(4):234-42. PubMed ID: 12666133
[TBL] [Abstract][Full Text] [Related]
13. Binding and activation of plasminogen at the surface of human keratinocytes.
Reinartz J; Batrla R; Boukamp P; Fusenig N; Kramer MD
Exp Cell Res; 1993 Sep; 208(1):197-208. PubMed ID: 8359216
[TBL] [Abstract][Full Text] [Related]
14. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Cohen RL; Xi XP; Crowley CW; Lucas BK; Levinson AD; Shuman MA
Blood; 1991 Jul; 78(2):479-87. PubMed ID: 1648983
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
[TBL] [Abstract][Full Text] [Related]
17. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
18. Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells.
Ellis V; Whawell SA
Blood; 1997 Sep; 90(6):2312-22. PubMed ID: 9310482
[TBL] [Abstract][Full Text] [Related]
19. Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation.
Hägglund AC; Ny A; Liu K; Ny T
Endocrinology; 1996 Dec; 137(12):5671-7. PubMed ID: 8940398
[TBL] [Abstract][Full Text] [Related]
20. Neuronal plasminogen activators: cell surface binding sites and involvement in neurite outgrowth.
Pittman RN; Ivins JK; Buettner HM
J Neurosci; 1989 Dec; 9(12):4269-86. PubMed ID: 2512375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
